WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Calgary, Alberta – May 12, 2025 – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQB: CANSF), announces its unaudited consolidated interim financial statements and related management’s discussion and analysis (“MD&A“) for the quarter ended March 31, 2025, are available on the Company’s SEDAR+ profile at www.sedarplus.ca. About Willow Biosciences Willow Biosciences Inc. is a corporation […]

WILLOW BIOSCIENCES INC. RECEIVES FIRM COMMITMENTS OF $30.0 MILLION UNDER PREVIOUSLY ANNOUNCED RECAPITALIZATION FINANCING

Calgary, Alberta – May 8, 2025 –Willow Biosciences Inc. (the “Company”) (TSX: WLLW) (OTCQB: CANSF) is pleased to announce that it has received firm commitments to purchase an aggregate of $30.0 million of equity securities pursuant to the previously announced non-brokered private placement (the “Private Placement”), with demand significantly exceeding that amount. The completion of the […]

WILLOW BIOSCIENCES INC. ANNOUNCES $30.0 MILLION RECAPITALIZATION FINANCING AND PROPOSED APPOINTMENT OF NEW EXECUTIVE TEAM AND BOARD OF DIRECTORS TO FORM ATLAS ENERGY CORP.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW. Calgary, Alberta – May 7, 2025 –Willow Biosciences Inc. (the “Company”) (TSX: WLLW) (OTCQB: CANSF) is pleased to announce that it has entered into a definitive […]

 WILLOW BIOSCIENCES INC. ANNOUNCESCOMPLETION OF SALE OF OPERATING SUBSIDIARY AND MANAGEMENT CHANGES

Calgary, Alberta – April 30, 2025 – Willow Biosciences Inc. (the “Company“) (TSX: WLLW) (OTCQB: CANSF) announces the completion today of the sale (the “Transaction“) of its wholly-owned operating subsidiary, Epimeron USA, Inc., to the U.S. subsidiary of Mycofeast Ltd., a privately-held, arms-length entity based in the United Kingdom (the “Purchaser“), pursuant to the terms of […]

WILLOW BIOSCIENCES ANNOUNCESANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

Sunnyvale, California – April 25, 2025 – Willow Biosciences Inc.(“Willow” or the “Company“) (TSX: WLLW; OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on April 25, 2025 (the “Meeting“). A total of 59,214,893 common shares, representing approximately 40.88% of the Company’s issued and outstanding shares […]

WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY

Sunnyvale, California – March 24, 2025 – Willow Biosciences Inc.(“Willow” or the “Company”) (TSX: WLLW; OTCQB: CANSF), a biotechnology company focused on industrial manufacturing of ingredients is pleased to announce its financial and operating results for the three months and year ended December 31, 2024, and an update in respect of the disposition of Company’s operating […]

Mountain View, CA

Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.